John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

The University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

A Phase 1/1b first-in-human dose escalation and expansion study for theevaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult

Administered By
Duke Cancer Institute
Awarded By
Sanofi US
Role
Principal Investigator
Start Date
End Date

A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors

Administered By
Duke Cancer Institute
Awarded By
Curegenix Inc.
Role
Principal Investigator
Start Date
End Date

A PHASE Ib, MULTICENTER, OPEN-LABELSTUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABL

Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

Administered By
Duke Cancer Institute
Awarded By
Nektar Therapeutics
Role
Principal Investigator
Start Date
End Date

Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab

Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)

Authors
André, T; Bekaii-Saab, T; Tabernero, J; Siena, S; Yoshino, T; Norwood, KG; Adelberg, DE; Ward, J; Yang, S; Strickler, JH; Van Cutsem, E
MLA Citation
André, T., et al. “438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S734–35. Crossref, doi:10.1016/j.annonc.2022.07.576.
URI
https://scholars.duke.edu/individual/pub1560067
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S734
End Page
S735
DOI
10.1016/j.annonc.2022.07.576

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Authors
Kuboki, Y; Yaeger, R; Fakih, MG; Strickler, JH; Masuishi, T; Kim, EJ; Bestvina, CM; Langer, CJ; Krauss, JC; Puri, S; Cardona, P; Chan, E; Tran, Q; Hong, DS
MLA Citation
Kuboki, Y., et al. “315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S680–81. Crossref, doi:10.1016/j.annonc.2022.07.453.
URI
https://scholars.duke.edu/individual/pub1560068
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S680
End Page
S681
DOI
10.1016/j.annonc.2022.07.453

376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes

Authors
Bekaii-Saab, T; Lach, K; Hsu, L-I; Siadak, MF; Stecher, M; Ward, J; Beckerman, R; Strickler, JH
MLA Citation
Bekaii-Saab, T., et al. “376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S708–S708. Crossref, doi:10.1016/j.annonc.2022.07.514.
URI
https://scholars.duke.edu/individual/pub1560069
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S708
End Page
S708
DOI
10.1016/j.annonc.2022.07.514

361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER

Authors
Wu, C; Strickler, JH; Cercek, A; Siena, S; André, T; Ng, K; Van Cutsem, E; Paulson, AS; Hubbard, J; Coveler, A; Fountzilas, C; Kardosh, A; Kasi, PM; Lenz, HJ; Ciombor, KK; Elez Fernandez, ME; Hsu, L-I; Stecher, M; Zhao, K; Bekaii-Saab, T
MLA Citation
Wu, C., et al. “361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S700–01. Crossref, doi:10.1016/j.annonc.2022.07.499.
URI
https://scholars.duke.edu/individual/pub1560070
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S700
End Page
S701
DOI
10.1016/j.annonc.2022.07.499

LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC

Authors
Strickler, JH; Cercek, A; Siena, S; André, T; Ng, K; Van Cutsem, E; Wu, C; Paulson, AS; Hubbard, J; Coveler, A; Fountzilas, C; Kardosh, A; Kasi, PM; Lenz, HJ; Ciombor, KK; Fernandez, MEE; Bajor, DL; Stecher, M; Feng, W; Bekaii-Saab, T
MLA Citation
Strickler, J. H., et al. “LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1394–S1394. Crossref, doi:10.1016/j.annonc.2022.08.023.
URI
https://scholars.duke.edu/individual/pub1560071
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1394
End Page
S1394
DOI
10.1016/j.annonc.2022.08.023